Reozalimab

N/A

Report date: 2023/12/06 13:51:46

Base Information

Drug NameReozalimab
Drug Alias NameIBI318IBI-318LY-3434172LY3434172
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProgrammed cell death protein 1 blockersProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1Programmed cell death protein 1
Therapy Area/IndicationsSmall Cell Lung CarcinomaCarcinoma, Squamous CellCarcinoma, Hepatocellular +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesInnovent Biologics(Suzhou) Co LtdEli Lilly And Company
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesEli Lilly And CompanyInnovent Biologics(Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung Carcinoma
Inactive IndicationsCarcinoma, Squamous CellCarcinoma, HepatocellularLymphoma, Extranodal NK-T-Cell +[4] 

Other Information

ATC CodeN/A
Related LinksN/A